boldcommitment

our commitment is real

Relentless in our mission to positively impact the rare disease community, we seek to include individuals and their families in every aspect of what we do. And that’s because at Ovid, we believe that having a deep and true understanding of what it’s like to live with a rare neurological disease is key to addressing significant unmet needs.

Here, the patient community is our community. Each relationship we foster brings us closer and closer to making meaningful medicines readily available to those who may benefit.

Hear more about our community-first approach to rare neurological diseases:

the who behind our why

featured patient story

take a deeper look

community events

ASF Angelman walk

RareVoice Awards

Community Congress Annual In-Person Meeting

LGS Family and Scientific Conference

NORD Rare Diseases and Orphan Products Breakthrough Summit

RARE Patient Advocacy Summit

engagement powered by purpose

Partnering with patient advocacy groups and foundations puts us on the ground with those fighting for a better future. Working shoulder to shoulder, our relationships with these organizations are personal—united in our passion to make meaningful change happen.

The mission of the Angelman Syndrome Foundation is to advance the awareness and treatment of Angelman syndrome through education and information, research and support for individuals with Angelman syndrome, their families and other concerned parties. The ASF exists to give all of them a reason to smile, with the ultimate goal of finding a cure.

Visit Site

The foundation is committed to assisting individuals living with Angelman syndrome to realize their full potential and quality of life. Their goal is to bring practical treatment into current medical practice as quickly as possible.

Visit Site

⦁ Along with funding research, FRAXA runs scientific meetings, advises pharmaceutical companies large and small, and provides education on college campuses, community settings, and international conferences. Families can reach out to FRAXA for resources, guidance, referrals and an international community of support.

Visit Site

The National Fragile X Foundation serves all those living with Fragile X with a focus on community, awareness, and research in the pursuit of treatments and a cure. Their mission is to provide unwavering support for every family affected by Fragile X, while relentlessly pursuing a cure.

Visit Site

EURORDIS-Rare Diseases Europe is a unique, nonprofit alliance of 869 rare disease patient organizations from 71 countries that work together to improve the lives of the 30 million people living with a rare disease in Europe.

Visit Site

The mission of Dravet Syndrome Foundation (DSF) is to aggressively raise research funds for Dravet syndrome and related epilepsies; to increase awareness of these catastrophic conditions; and to provide support to affected individuals and families.

Visit Site

The IFCR is committed to funding research, both scientific and clinical, that will bring about treatments and, ultimately, a cure for CDKL5. They seek to support all CDKL5 families and caregivers, whether newly diagnosed or well into adulthood, by providing the most current information on treatment advances and how to live their best life possible.

Visit Site

The LGS Foundation's mission is to improve the lives of individuals affected by Lennox-Gastaut Syndrome (LGS) through research, family support programs and education.

Visit Site

The Rare Epilepsy Network, or REN for short, is a collaboration between the Epilepsy Foundation, the IFCR, RTI international, Columbia University, and many different organizations that represent patients with a rare syndrome or disorder that is associated with epilepsy or seizures.

Visit Site

Global Genes groups are the friends, family and supporters of the patients who are affected by rare disease. They understand the confusion, the overwhelming experience of the unknown and the feelings of isolation all too well. The reason Global Genes was born is to connect, empower and inspire the rare disease community.

Visit Site

Loulou Foundation is a private nonprofit UK foundation dedicated to advancing research into the understanding and development of therapeutics for CDKL5 deficiency disorder.

Visit Site

The Epilepsy Foundation exists to end epilepsy. That means increasing awareness and changing the conversation around epilepsy, improving and saving lives through care, advocacy, research and new therapies, and education, and mobilizing everyone to take action.

Visit Site

NORD, a 501(c)(3) organization, is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with its more than 280 patient organization members, is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services.

Visit Site

For the past twenty-two years, Dup15q Alliance has provided family support and promoted awareness, research and targeted treatments for chromosome 15q11.2-13.1 duplication syndrome.

Visit Site

Expanded Access Program

Ovid is driven by the passion to improve the lives of individuals and their families by working to develop new medicines for individuals living with rare and serious illnesses. As a company, we want to bring our medicines to the largest numbers of people who may potentially benefit from them. At the same time, we have a duty to balance this desire while ensuring that our investigational drugs are both safe and effective before making them available outside of the controlled setting of clinical studies.

Currently, Ovid Therapeutics does not have an Expanded Access Program for its pipeline compounds, but is evaluating the potential for an expanded access program for OV101 (gaboxadol) and OV935 (soticlestat) and will work with regulators to determine the best path forward.

We understand that individuals with Angelman syndrome, Fragile X syndrome and rare epilepsies do not have many options to address their medical needs. Investigational clinical studies are the fastest path to bring forward a potential treatment these rare neurological conditions. Because our goal is to help as many individuals as possible, as quickly as possible, access to the investigational therapy outside of a clinical trial must not adversely impact or delay the clinical studies involving the investigational therapy so that we can meet rigorous medical and regulatory requirements before making a potential treatment option widely available.

At times, a physician may seek access to therapeutics in early development, not yet approved by regulatory agencies, for an individual with a life-threatening or serious disease who has exhausted all medical options. This use of a drug candidate outside of the context of a clinical trial is called expanded access, among other names.

The following is additional information regarding Ovid’s expanded access policy in accordance with the 21st Century Cures Act:

⦁ Contact Information: If you have any questions regarding Ovid’s expanded access policy in general, please contact eap@ovidrx.com. If you have any questions regarding potential participation in Ovid’s clinical trials, please contact us by email at clinical@ovidrx.com.

⦁ General Criteria: If Ovid opens an expanded access program, we will update this policy and provide appropriate details.

⦁ Response Timing: If you contact Ovid as described above, we will acknowledge receipt within five business days.

clinical studies

Our studies are exploring potential treatments that could be the first to make a meaningful impact in the lives of individuals with rare neurological diseases.

See all clinical studies »

grants, sponsorships and charitable contributions

Driven by our passion, Ovid aims to positively impact the lives of patients, communities and healthcare workers by supporting various various activities and organizations.

Learn more about this program »

boldcommitment

our commitment is real

the who behind our why

Meet Rhys, a young boy with Angelman syndrome

take a deeper look

Life with Angelman Syndrome: Small Victories, Big Impact

Life with CDKL5 deficiency disorder: Tanner's Story

Life with Angelman Syndrome: The Impact of Sleep Deprivation

community events

engagement powered by purpose

clinical studies

grants, sponsorships and charitable contributions